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Available online 12 March 2016Background and purpose: In treating glioblastoma (GB), surgical and chemotherapeutic treatment guidelines are,
for the most part, independent of tumor location. In this work, we compiled imaging data from a large cohort
of GB patients to create statistical atlases illustrating the disease spatial frequency as a function of patient
demographics as well as tumor characteristics.
Materials and methods: Two-hundred-six patients with pathology-proven glioblastoma were included. Of those,
65 had pathology-proven recurrence and 113 hadmolecular subtype and genetic information.Weused validated
software to segment the tumors in all patients and map them from patient space into a common template. We
then created statistical maps that described the spatial location of tumors with respect to demographics and
tumor characteristics. We applied a chi-square test to determine whether pattern differences were statistically
signiﬁcant.
Results: The most frequent location for glioblastoma in our patient population is the right temporal lobe.
There are statistically signiﬁcant differences when comparing patterns using demographic data such as gender
(p = 0.0006) and age (p = 0.006). Small and large tumors tend to occur in separate locations (p = 0.0007).
The tumors tend to occur in different locations according to their molecular subtypes (p b 10−6). The classical
subtype tends to spare the frontal lobes, the neural subtype tend to involve the inferior right frontal lobe.
Although the sample size is limited, there was a difference in location according to EGFR VIII genotype
(p b 10−4), with a right temporal dominance for EFGR VIII negative tumors, and frontal lobe dominance in
EGFR VIII positive tumors.
Conclusions: Spatial location of GB is an important factor that correlates with demographic factors and tumor
characteristics, which should therefore be considered when evaluating a patient with GB and might assist in
personalized treatment.







Glioblastoma (GB) is the most aggressive adult primary brain neo-
plasm and accounts for 54% of all glial tumors. Despite recent diagnostic
and therapeutic advances, the prognosis remains poor with a reported
median survival of only about 14 months (Van Meir et al., 2010). The
current standard of care for newly diagnosed GB is maximal safe resec-
tion and concurrent temozolomide (TMZ) and radiation therapy. The
persistent unfavorable prognosis has prompted continued efforts to
better understand the behavior of this neoplasm, particularly in termsmilton Walk, Philadelphia, PA
. This is an open access article underof recurrence. Although there is evidence that tumor location correlates
with prognosis, surgical and chemotherapeutic treatment guidelines
are, for the most part, independent of tumor location, except for the
attention given to surrounding eloquent structures at surgery.
Probabilistic atlases have become a key component of structural and
functional analysis in image-based neurosciences (Lee and Lee, 2005).
Beneﬁting from the development of spatial normalization techniques,
they allow for meaningful assessments of brain anatomical or patholog-
ical features due to several advantages. First, they provide a population-
based standard foundation for comparing a subject’s brain characteristics
to that of his or her peers in the same population (Thompson et al.,
2000). Second, by construction, statistical atlases are more accurate in
their representation of a particular population than models built on a
single subject or other type of general knowledge. Third, statistical
atlases integrate information on individual variability and can revealthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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otherwise (Bilello et al., 2006).
In this work, we compiled imaging data from a large cohort of GB
patients to create statistical atlases illustrating the tumoral spatial
frequency as a function of several demographic factors, such as age
and gender. In addition, we constructed atlases related to spatial
location of GB tumor recurrence, molecular mutation, and molecular
class using a subset of these patients with pathologically conﬁrmed
neoplastic recurrence. Other investigators have created similar atlases
for low-grade gliomas (Parisot et al., 2016).
We investigated whether these tumors are distributed uniformly or
whether certain brain regions are relatively more vulnerable to tumor
formation in certain patient sub-populations. We hypothesize that
spatial localization of tumor will be speciﬁc to site of tumor origin or
molecular features of the tumor. Further delineation of such spatial
patterns may increase understanding of underlying tumor pathophysi-
ology and can inform diagnosis and treatment, especially as it relates
to the likelihood of tumor occurrence at a given location.
2. Materials and methods
2.1. Subjects
Two hundred and six patients with newly diagnosed, pathology-
proven GB were included in this retrospective, HIPAA-compliant, IRB-
approved study. All patients underwent imaging at time of diagnosis
utilizing the brain tumor MRI protocol of the Hospital of the University
of Pennsylvania between 2006 and 2013. All patients underwent
maximal safe resection, radiotherapy, and concomitant and adjuvant
chemotherapy with temozolomide, according to standard of care.
Surveillance MRI scans were obtained as clinically warranted. Of those
206 patients, 65 had disease recurrence, which was pathology-proven
after re-resection. The time to recurrencewas the time elapsed between
the initial MRI scan and the follow-up MRI scan that preceded the re-
resection, with recurrence demonstrated on pathology.
2.2. MRI protocol
All images were acquired on a Siemens TrioTim 3.0 Tesla scanner
and included the following sequences: pre- and post-gadolinium axial
high-resolution, 1-mm isotropic T1, 3D MPRAGE (magnetization-
prepared gradient echo), axial 2D T2-FLAIR (ﬂuid-attenuated inversion
recovery), axial 2D T2-weighted.
2.3. Image processing
To construct the brain tumor atlas that captures the statistics of the
spatial distribution of GB in the population, we have employed Glioma
Image Segmentation and Registration (GLISTR) software developed in
our lab (Gooya et al., 2012). The program uses the T2-FLAIR, T2, and
pre- and post-gadolinium T1 sequences. In this scheme, the tumor
segmentation includes both enhancing and non-enhancing necrotic
components. The segmented tumor of each patient is then registered
into the common atlas space.
GLISTR simultaneously registers a probabilistic atlas of a healthy
population to the MR images with glioblastoma and segments the
images into enhancing and non-enhancing tumor, peritumoral edema,
and healthy tissue labels. This method uses the Expectation Maximiza-
tion (EM) algorithm, and incorporates a tumor growthmodel, a process
which modiﬁes the original atlas into an image with tumor and edema
adapted to best match a given set of patient images. The modiﬁed atlas
is registered into the patient images, and then GLISTR utilizes this
process for estimating the posterior probabilities of various tissue labels.
EM iteratively reﬁnes the estimates of the posterior probabilities of
tissue labels, the deformation ﬁeld, and the tumor growth model
parameters. The deformation ﬁeld takes into account the mass effectproduced by the tumor. Therefore, GLISTR has a framework for joint
segmentation and non-linear registration that is guided by the atlas.
The inverted deformation ﬁeld warps the patient images into the com-
mon atlas space. The mass effect was relaxed in the atlas-normalized
images, hence the ventricles seem to be decompressed compared to
the original patients’ scans. This method thus incorporates a tumor
growthmodel to adapt the normal atlas into the anatomy of the patient
brain (Gooya et al., 2012).
2.4. Statistical atlases
The statistical atlases are constructed by superimposing all warped
label maps over the patient population based on different groups,
including entire population, age, gender, size of tumor, and tumor recur-
rence, and computing the spatial frequency of tumor occurrence at each
voxel in the template space. The frequency is then color coded for easier
visualization. For a group of tumors (T1, T2,…, TN), where a tumor Tn is
deﬁned here as the cluster of voxels corresponding to enhancing and
necrotic components. The statistical atlas at voxel i is computed as the
number of tumors that intersect voxel i divided by N, the total number
of tumors used to build the atlas.
To visualize age-related distributions, we divided the subjects into
two age groups, younger or older than the median age. Similarly, to
display the effect of tumor volume on spatial distribution, we separated
the lesions into 2 groups, i.e., smaller or larger than themedian of tumor
volumes.Weused themedian time to recurrence (6.7months) to divide
patients according to time to recurrence. For survival, the patients were
divided into two groups based on the median (14.6 months), and the
chi-square statistical test was performed. Then, to enhance the
difference in the short survival patients, these patients were divided
again based on their median (6months). Therefore, short, intermediate,
and long survival times were determined relative to 6 months and
14.6 months.
2.5. Statistical analysis
Distribution pattern analysis is employed in this study to demon-
strate spatial relationships among subjects in the dataset. We exam-
ine the spatial relationship among the location of the tumors in the
template brain, which has been parcellated into several regions of
interests (ROI). The spatial analysis method of describing the dataset
pattern is performed through frequency of tumor occurrence in
each ROI. One of the most common and useful ways to examine
differences between two sets with categorical variables is the
Pearson’s chi-square test, which evaluates the likelihood that any
observed difference between the sets arises by chance (Agresti and
Kateri, 2011).
The null hypothesis is that the number of tumors in each ROI is
spatially random (Poisson distribution). A spatial Poisson process or
complete spatial randomness (CSR) describes a point distribution
process within a given study area that is completely random. The
process ismodeled using only one parameter, i.e., the number of tumors
in each ROI, normalized by the ROI size. The expected and observed
point distribution is calculated using the Poisson distribution, and
then the statistical chi-square test is used to infer properties about the
dataset, i.e., whether the spatial point patterns are random, clustered
or dispersed. Thus, the chi-square test is used to determine whether
we should reject or fail to reject the spatial randomness hypothesis.
Then, all patients were divided to two groups based on median of age,
size of tumor, survival, time to recurrence, gender, and EGFR VIII status.
Each pair of tumor distributions was separately compared through
Pearson’s chi-square test to identify whether or not the distributions
of tumors between two groups are different. The median was selected
as the threshold to divide the patients to two groups to have almost
equal number in each group. A p value less or equal to 0.05 was consid-
ered statistically signiﬁcant.
Fig. 1. Frequency distribution of tumor (all subjects). The color look-up table shows the
frequency inpercent. All imageswere displayed in the radiological convention orientation.
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3.1. Patient population
Table 1 contains details about subject demographics, tumor charac-
teristics, such as volume andmolecular subtype, and time to recurrence.
The most frequent tumor location in our patient population was the
frontotemporal region, perisylvian region, around the temporal horns,
with slightly higher probability on the right, with other signiﬁcant clus-
ters in the frontal lobes and left frontoparietal region (Fig. 1). The
highest probability is associated with the subcortical white matter
with extension to the grey matter for tumors in the temporal lobe.
There is otherwise a diffuse distribution, bilateral occipital lobes being
relatively spared, while the posterior fossa is completely uninvolved.
The frequency distribution is different from a Poisson’s distribution
(p= 8.5 × 10−18).
3.2. Age
When subjects are stratiﬁed by age, as in Fig. 2, the tumors localize to
the bilateral frontotemporal lobes in older patients, and involve more
the periventricular frontal lobes in younger patients. There is more
frequent involvement of the superior, subcortical frontal lobes in older
patients, as well as complete sparing of the occipital lobes. No tumors
were found in the cerebellum. The tumor distribution in younger
patients (b62 years) is signiﬁcantly different from that in older patients
(N62 years) (p= 0.006).
3.3. Gender
Fig. 2 displays the distribution of tumors by gender. In women, there
is a strong, asymmetric right temporal cluster, whereas in men, the left
temporal lobe is more involved. These differences extend to the
periventricular frontal regions (right for women, left for men). There
is a statistically signiﬁcant difference between the distributions of
tumors in women and men (p= 0.0006).
Additionally, t-test was utilized to evaluate the size of tumors inmen
and women. There was a statistically signiﬁcant (p= 0.005) difference
in size of tumor between men and women. The mean tumor size was
11.701 cm3 for men vs. 15.021 cm3 for women. The size of enhancing
tumor was also found to be signiﬁcantly different (p= 0.01) between
the genders, 6.790 cm3 for men vs. 8.649 cm3 for women.
There was also a statistically signiﬁcant (p=0.01) difference in size
of necrotic tumor betweenwomen andmen, 4.9 cm3 formen vs. 6.4 cm3
for women. However, the size of enhancing and necrotic tumor was
larger in women because the total tumor size is larger. In other words,
therewas no statistically signiﬁcant difference in the relative proportion
of enhancing or necrotic components.Moreover, the difference of size ofTable 1
Subject demographics and tumor characteristics.
Gender EGFR VIII Subtype
Male Female Negative Positive M N PN CL
116 90 49 15 30 34 28 21
Survival (Months) Less than 6 Between 6 & 14.6 More than 14.6
Number 47 49 102
Max Min Mean Median Std
Age (Years) 88 22 62 62 12.3
Volume (cm3) 62.2 1.9 13.1 11.1 8.42
TTRa (Months) 34.5 1.0 8.2 6.7 6.37
Abbreviations: EGFR = epidermal growth factor receptor, M=mesenchymal, N = neural,
PN = proneural, CL = classical, std = standard deviation, TTR = Time to Recurrence.
a 65 subjects with recurrence.surrounding T2-FLAIR signal abnormality between men and women
was not signiﬁcantly different.
3.4. Tumor volume
In Fig. 2, the distributions with respect to volume of tumors are
displayed. There is a clear distinction with regards to localization in
the frontotemporal regions, where large tumors tend to occur on the
right side, and small tumors on the left. These differences extend to
the periventricular frontal regions. Other important clusters include
the right frontal lobe and right thalamus. The distribution of large
tumors differs signiﬁcantly to that of small tumors (p= 0.0007).
3.5. Time to recurrence
Among the cases with documented recurrence, we divided the tu-
mors in two groups, by the median time to recurrence (6.7 months).
The atlas is shown in Fig. 2. There is a high likelihood cluster of short
time to recurrence tumors in the left frontal lobe, while long time to
recurrence tumors appear to occurwith high probability in the right tem-
poral lobe. The distribution of the tumors with short time to recurrence
differs signiﬁcantly to that of long time to recurrence tumors (p=0.001).
3.6. Survival
Tumors associated with short survival tend to occur in the left
frontotemporal region, whereas tumors associated with long survival
occur more frequently in the right frontotemporal region, as well as in
the frontal lobes, as shown in Fig. 3. The distribution of the tumors
with short survival differs signiﬁcantly to that of long survival (divided
by median) with p= 0.0008.
3.7. EGFR VIII status
As shown in Fig. 2, there is a strong right frontotemporal cluster of
tumor occurrence in subjects with EGFR VIII negative tumors, which is
absent in the subgroup with EGFR VIII positive tumors. There is also
frontal lobe dominance in EGFR VIII positive tumors. The distribution
of the tumors with positive EGFR VIII status differs signiﬁcantly to that
of negative EGFR VIII negative tumors (p= 0.00009).
3.8. Molecular subtype
There was a statistically signiﬁcant difference in the distribution
of tumors according to molecular subtype (p = 3.4 × 10−7) as shown
in Fig. 4. The distribution for the classical was particularly different
from the others, probably because of its lack of anterior frontal lobe
involvement. In addition, there is distinct inferior right frontal lobe
involvement in the neural subtype.
Fig. 2. Frequency distribution of tumor by age, gender, size of tumor, time to recurrence (TTR), andEGFRVIII status. The color look-up table shows the frequency inpercent. All imageswere
displayed in the radiological convention orientation.
Fig. 3. Frequency distribution by survival. The color look-up table shows the frequency in percent. All images were displayed in the radiological convention orientation.
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Fig. 4. Frequency distribution by molecular subtype. All images were displayed in the radiological convention orientation.
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Based onMR images from a large cohort of patientswith de novo GB,
we created distinct spatial maps of tumor location as a function of
several patient, tumor, and molecular features. Enhancing and non-
enhancing tumor regions on MR images were segmented and then
registered to a normalized atlas in order to generate statistical maps
speciﬁc to age, gender, tumor volume, time to recurrence, survival,
and tumor molecular status. Differences between maps were then
compared using distribution pattern analysis. Such population-based
MRI atlases represent the imaging phenotype for GBs in relation to
multiple variables.
4.1. Tumor location
The spatial distribution of GBs in our study is consistent with ﬁnd-
ings of related studies and with the presumed sites of tumor cell origin.
The detection of cancer stem cells within GBs has fueled the notion thatGBs arise from altered precursor neural stem cells (Lim et al., 2007;
Sanai et al., 2005), which are located primarily in a region along the
walls of the lateral ventricles known as the subventricular zone (SVZ).
Consequently, several studies have documented the frequent occur-
rence of GBs in the posterior SVZ (Kimura et al., 2013; Wang et al.,
2015). Although we noted tumor in a frontoparietal periventricular
white matter distribution less frequently than other groups (Ellingson
et al., 2013), we found a strong bilateral frontotemporal distribution of
GB, similar to a prior study (Lee et al., 2010). A SVZ exists around the
temporal horns, making our ﬁndings consistent with the notion that
tumor location may represent the contribution of region-speciﬁc
precursor cells. Still, not all tumors in our study were intimately related
to the SVZ, aswe found clusters in the perisylvian area, aswell as in sub-
cortical white matter with extension to grey matter. Neural stem cells
have been found in other regions of the brain, such as the dentate
gyrus (Hagg, 2009). Furthermore, other studies have demonstrated
that cycling progenitors distributed throughout the subcortical white
matter may contribute to GB tumor growth (Bohman et al., 2010).
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ally, access to blood supply from large branches of the middle cerebral
arteries may be an important factor in glioblastoma spatial distribution.
In our study we did not ﬁnd any tumors in the cerebellum. Primary
cerebellar GBM is considered a rare tumor in adults and reportedly
accounts for just 1% of all cases of GBM. Due to their rarity, the exact
pathogenesis and prognosis of cerebellar GBMs is not yet completely
understood. It is proposed that cerebellar astrocytes have lesser tenden-
cy to become malignant (Hur et al., 2008).
4.2. Age and gender
Tumor spatial localization among GB patients differs based on age
and gender. Several studies have shown a higher incidence of frontal
lobe tumors in younger patients (Dunn et al., 2012; Ellingson et al.,
2013; Lai et al., 2011), which is thought to be related to the co-
localization of IDH1 mutant tumors to the bifrontal regions (Lai et al.,
2011). The IDH1 gene encodes a metabolic enzyme called isocitrate
dehydrogenase, and IDH1mutant occursmore commonly in younger pa-
tients. Althoughwe also noted frontal lobe involvement more frequently
in younger patients, GB was more common in the periventricular frontal
whitematter in our cohort rather than subcortical frontalwhitematter in
other studies (Ellingson et al., 2013). In older patients, GB was more
frequently found in bilateral temporal lobes. Wang et al. noted increased
frequency of bilateral temporal lobe GB among patients with advanced
age, especially at the posterior region of the SVZ (Wang et al., 2015).
Based on the correlation between tumor location and age, the authors
hypothesized that GB has a different site of origin in younger vs. older
patients.
Aside from the observation that GB occursmore frequently inmales,
the impact of gender on tumorigenesis in GB has not been thoroughly
investigated. In an animal model of GB, MR images of male rats with
high grade gliomas showed increased cell proliferation, vasogenic
edema, and necrosis compared to females (Pérez-Carro et al., 2014).
Furthermore, in humans, transcription factor analysis was used to
show that cell death in female GB patients occurs via a signaling
pathway associated with MYC, whereas it occurs in association with
TP53 in male patients (Colen et al., 2015). Such gender difference may
apply to other pathways within GB tumors and manifest as varying
imaging phenotypes.
The differences of distribution observed between genders may be at-
tributed to hormonal physiology, whichmay have spatial speciﬁcity. Sex
steroids have been implicated in “gender-neutral” cancers (Folkerd and
Dowsett, 2010), although no current evidence indicates that glial tumors
are affected. There is, however, evidence that sex hormones are able to
cross the blood-brain barrier (Brodal, 2004). The strong lateralization
observed between genders is certainly intriguing, and to our knowledge,
has not been reported in prior studies. In addition, our study conﬁrms a
previously reported result that tumors in women have larger areas of
necrosis, perhaps accounting for a larger overall cross sectional size of
the tumor (Colen et al., 2015). We also found that tumors in women
are larger, but with larger enhancing components as well.
4.3. Tumor volume, time to recurrence, and survival
Differences in spatial maps of tumor size likely relate to the function
of surrounding cortex. For instance, tumors in eloquent areas of the
brain, even small ones, are more likely to be symptomatic and prompt
medical attention earlier as compared to similarly sized tumors in
non-eloquent regions. Left frontotemporal tumors, the most common
site for smaller tumors in our study, may affect language centers and
therefore be detected sooner. Similar reasons may explain why lesions
occurring in the right thalamus are relatively small, as tumors in that
location are expected to cause elevated intracranial pressure, by
obstructing cerebrospinal ﬂuid drainage, and motor deﬁcits (Tonn
et al., 2010).Our time to recurrence atlas shows a strong cluster in the left frontal
subcortical and deep white matter that was associated with rapid
recurrence, whereas other authors found a periventricular distribution
of GB to be associated with early recurrence (Ellingson et al., 2013).
Our pattern associated with long time to recurrence was similar to
results of another population-based statistical atlas in GB that showed
clusters in the right temporal and left perisylvian regions (Ellingson
et al., 2013). Shorter time to recurrence in some areasmay be the result
of limited surgical resection (e.g., to spare nearby eloquent structures,
such as the language centers of the left frontotemporal lobes in most
patients) or tendency for tumors in those locations to be more aggres-
sive. However, the marked differences in spatial distribution between
short and long recurrence subgroups indicates that spatial location can
potentially be a valuable predictor of time to recurrence.
There are similarities between the recurrence and the survival
atlases, which probably reﬂect the fact that early recurrence correlates
with shorter survival. There is a higher frequency of periventricular
tumors associated with short and medium survival, a ﬁnding that con-
ﬁrms results reported in a study of GB assessing the association between
tumor distance to the ventricle and survival (Chaichana et al., 2008).
Shorter survival was associated with a left frontotemporal cluster,
whereas right-sided frontotemporal tumors had a longer survival. This
appears to contradict results reported in a related study (Ellingson
et al., 2013); however, the difference may be in part related to the cho-
sen deﬁnition of short vs. long survival. The authors used b12months or
N36 months to deﬁne overall survival, whereas we divided survival to
b6 months, between 6 and 14.6 months, and N14.6 months. Another
study found frontal location of tumors in general to be associated with
improved survival, although the studywas not restricted to patients un-
dergoing gross total resection (Simpson et al., 1993). These observations
are consistent with GBs being commonly located near the SVZ and this
location being associated with decreased survival (Adeberg et al., 2014;
Jafri et al., 2013). It is postulated that tumors originating from this re-
gion are innately more invasive or are near a high density of subcortical
ﬁbers along which they can track.
4.4. EGFR VIII status and molecular subtype
We found a strong cluster of EGFR VIII negative tumors in the right
frontotemporal region; however, our results differ from a predomi-
nance of EGFR VIII positive tumors in the left temporal lobe, as reported
in a related study (Ellingson et al., 2013). The discrepancymay be due to
the relatively low number of EGFR VIII positive glioblastomas in our
patient population. Although there was suggestion of a bifrontal
propensity in the proneural tumor distribution, as reported in the
same study (Ellingson et al., 2013), we did not ﬁnd a right-sided pre-
dominance in mesenchymal tumors.
The use of population-based spatial localization maps in GB, when
taken together, demonstrates a complex interplay between individual
patient, tumor, and molecular characteristics. For example, the EGFR
mutation is a main driver of the classical subgroup; however, we
found that the EGFR VIII positive map is different from the classical
subtype map. In our patient cohort, EGFR VIII positive tumors were
most likely to occur with frontal lobe dominance, whereas GBs of the
classical subtype lacked anterior frontal lobe involvement. Similarly,
the mesenchymal subtype is associated with shorter survival. Although
this subtype was found mainly in the right temporal location in our
study, the right temporal location was found to be more commonly
associated with longer, rather than shorter survival. Other groups
showed concordance with the left temporal lobe being associated
with mesenchymal gene expression, IDH 1 wild type, and decreased
survival (Ellingson et al., 2013). These results emphasize the complexity
between molecular subtypes, deﬁned by numerous mutations, and
spatial localization.
Several patient features were lateralized based on the spatial maps.
Although the exact mechanism is unclear, there are several instances
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including hemispheric lateralization of language and spatial representa-
tions (Sun and Walsh, 2006). In terms of GB tumor genetic expression,
related studies have shown the O6-methylguanine DNA methyltrans-
ferase (MGMT) promoter methylation is lateralized to the left temporal
lobe while MGMT unmethylated GBs are more commonly found in the
right hemisphere (Ellingson et al., 2012). Thus, our lateralized pheno-
types noted for several of the molecular subtype maps, as well tumor
size and recurrence maps, have multiple precedents in the human
brain, although the exact mechanism is unknown. Nonetheless, such
ﬁndings would not be recognized without the use of population-based
MR statistical atlases.4.5. Limitations
Our study has several limitations. One of the limitations of our work
stems from the relative low number of cases on which the atlases were
drawn, especially cases with genetic information. By essence, statistical
atlases becomemoremeaningful as the cases used for their construction
increases. Besides the relatively small number of cases, the atlas of
location frequency may be biased by disease severity. For instance, ful-
minant disease in certain locationsmay be lethal even before thepatient
gets imaging, although this is not supported by collective experience.
Alternate methods for atlas construction exist. In the most signiﬁcant
similar work in the literature, (Ellingson et al., 2013) generated spatial
maps using afﬁne transformations for registration of subject data to
template space. However, such an approach could considerably limit
spatial localization accuracy in the presence of signiﬁcant distortion
and mass effect, which are typical in glioblastoma. Our method uses
validated tumor growth-driven nonlinear registration to warp the
patients’ scans into the template space, and hence it offers much higher
localization accuracy.
Finally, as stated, more genetic information regarding the patients
could have enhanced the atlases. Just like genetics probably does not
explain all tumor behavior, it is not expected that the parameters we
used can do that either. A multifactorial combination of genetics,
demographics, physiology, including hormonal status, and lifestyle
parameters is probably required, but this would necessitate signiﬁcant
effort in screening subject history.5. Conclusions
The population-based MRI atlases generated in this study offer
evidence that the spatial location of GB is an important factor that
correlates with gender, age, tumor size, time-to-recurrence, survival,
EGFR VIII genotype, and molecular subtype, and should therefore be
considered along with other imaging and non-imaging variables when
evaluating a GB patient. For instance, a patient with a tumor that occurs
in a speciﬁc region strongly associated with early recurrence or short
survival may be a candidate for more aggressive adjuvant therapy,
such as radiation therapy, or early re-operation for recurrence. Although
we have put forth theoretical explanations for the statistical links
revealed by comparisons of spatial GB maps in this study, such mecha-
nisms remain unproven. It is our hope that the ﬁndings of this studywill
generate new hypotheses on tumor pathophysiology with regard to
tumor location, molecular proﬁle, cells of origin, and the inﬂuence of
surrounding brain regions.Acknowledgments
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